pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 15·1 min read
save

Amgen expands crackdown on what it says is misuse of 340B program

Amgen is expanding its claims data requirements for pharmacies dispensing its drugs under the 340B federal drug discount program. The company said the new policy addresses what it claims is fraud and misuse of the ...

May 15, 2026·read at Endpoints ↗

May 15, 2026 01:31 PM EDT Pharma Am­gen ex­pands crack­down on what it says is mis­use of 340B pro­gram Nicole DeFeudis Senior Reporter Am­gen is ex­pand­ing its claims da­ta re­quire­ments for phar­ma­cies dis­pens­ing its drugs un­der the 340B fed­er­al drug dis­count pro­gram. The com­pa­ny said the new pol­i­cy … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
83 words · retrieved May 15
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
AMGEN2

related stories

  • Jun 10Ethyreal starts up with $101M and takes aim at a pair of immune diseasesBioPharma Dive
  • Jun 8Tango data add to growing momentum for pancreatic cancer drugsBioPharma Dive
  • Jun 5Study data convince Lundbeck to push new migraine drug forwardBioPharma Dive
  • Jun 4STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?STAT
  • May 29Bristol Myers unveils data for one of its next-gen blood cancer drugsBioPharma Dive